Entera Bio

Entera Bio Gross Margin

The Gross Margin of Entera Bio (ENTX) as of Oct 8, 2026 is -71.43 %. In the previous year, Gross Margin was 4.97 % — a change of -1,536.51% (lower).

Gross Margin

-71.43 %

YoY

-1,536.51%

Last updated:

Gross Margin of Entera Bio is 2025 -71.43 % . Gross Margin of Entera Bio was 2024 4.97 % . It decreases by -1,536.51% lower compared to the previous year.

Entera Bio's gross margin stands at -71.4%, down from 34.7% several years earlier.

The Entera Bio Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
100.00 USD
Jan 1, 2019
-89.83 USD
Jan 1, 2020
42.74 USD
Jan 1, 2021
34.68 USD
Jan 1, 2022
24.63 USD
Jan 1, 2023
-400.00 USD
Jan 1, 2024
4.97 USD
Jan 1, 2025
-71.43 USD
The Entera Bio Gross Margin history
YEARGross MarginYoY
-71.43 %-1,536.51%
4.97 %-101.24%
-400.00 %-1,724.24%
24.63 %-28.98%
34.68 %-18.87%
42.74 %-147.58%
-89.83 %-189.83%
100.00 %—
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Gross Margin of Entera Bio is -71.43 % in 2025.

Gross Margin of Entera Bio changed from 4.97 % to -71.43 %, representing a -1,536.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Entera Bio

All Key Metrics — Entera Bio